Jul 2026
DNMT3B drives neuroendocrine lineage plasticity and aggressive progression in prostate cancer.
It is demonstrated that DNMT3B is required for both the initiation and maintenance of the NEPC phenotype, and its inhibition suppresses NEPC growth and differentiation, highlighting it as a promising therapeutic target for treatment-resistant disease.
Yunsol Jo, H. Jung, Zi-Qin Wang et al.
· Molecular Cancer Research · 0 citations